Myeloma News and Research

RSS

Research Paves Way for Off-the-Shelf CAR T Cells for Cancer Treatment

CAR T cell therapy is one of the most promising new cancer treatments to emerge in recent years. It involves removing a patient's own immune T cells and engineering them to recognize specific targets on the surface of the cancer cell.

31 Jan 2025

New Treatment Targets Tumor Microenvironment to Fight Breast Cancer

"Build your enemy a golden bridge to retreat across" is a piece of advice offered by Sun Tzu in his ancient military treatise, The Art of War. It turns out that cancerous growths adopt this strategy in their battle against the immune system.

24 Dec 2024

Dovetail Genomics Launches LinkPrep Technology for Enhanced Genetic Variant Discovery

Dovetail Genomics, a leading innovator in genomic solutions, today announces the commercial launch of its LinkPrep™ technology for genetic variant detection at American Society of Human Genetics (ASHG) conference.

4 Nov 2024

CRISPR and Antibodies Offer New Hope for Improving CAR-T Cell Therapy Outcomes

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason chimeric antigen receptor (CAR-T cell therapy) fails in some patients.

13 Sep 2024

Exploring Retrotransposon-Derived DNA Zip Codes in Myeloma Cell Internalization

A new editorial was published in Oncoscience (Volume 11) on July 13, 2024, entitled, "Unveiling retrotransposon-derived DNA zip code for myeloma cell internalization."

12 Aug 2024

Study Shows the Ability of Protein 'Signatures' to Predict Onset of 67 Diseases

Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of many diverse diseases.

24 Jul 2024

Enhancing Drug Discovery Through Automated Protein Labeling

Exact protein observation in cells is crucial for many scientific fields, but it has proven to be a difficult technical task, particularly in living cells where each protein needs to have its fluorescent label applied separately.

22 Apr 2024

Scientists Discover New Class of Molecular Glue Degraders for Cancer Therapy

Cells contain molecular machinery that targets and disposes of unwanted proteins to maintain homeostasis.

17 Nov 2023

New Insights Into Tumor-Immune Interactions Could Lead to More Effective Therapies for Multiple Myeloma

A multicenter study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine shows how interactions between tumor cells and immune components of the microenvironment can impact treatment responses and outcomes in patients newly diagnosed with multiple myeloma who undergo combination treatments that include targeted immunotherapy.

10 Nov 2023

Thermo Fisher Scientific Announces the Launch of the EXENT® Solution with IVDR Certification

Thermo Fisher Scientific, the world leader in serving science, today announced the commercial launch of the EXENT® Solution, after receiving IVDR certification.

28 Aug 2023

Scientists Uncover New Mechanism for Degrading Short-Lived Proteins

Short-lived proteins control gene expression in cells to carry out a number of vital tasks, from helping the brain form connections to helping the body mount an immune defense. These proteins are made in the nucleus and are quickly destroyed once they've done their job.

25 Aug 2023

High-Throughput Screening of Existing Drugs to Fight Multiple Myeloma More Effectively

Multiple myeloma is a rare blood cancer caused by the uncontrolled multiplication of abnormal plasma cells.

28 Apr 2023

Understanding the relationship between gut microbiome and CAR T-cell therapy response

Microorganisms live in or on almost every part of the human body and play an important role in the regulation of normal human processes. As a result, changes in the number or type of microorganisms, also known as the microbiome, can contribute to disease and altered responses to therapy, including cancer treatment.

14 Mar 2023

Whole genome sequencing might help better assess tumor evolution

To develop the most efficacious, personalized treatment plans for patients with Hodgkin lymphoma or other cancers, researchers and clinicians must first understand the genetic changes that cause cancer to develop.

23 Feb 2023

Reversal of ADAR1 hyper-editing with small molecule inhibitor

Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150.

17 Feb 2023

Cedars-Sinai's Stem Cell and Bone Marrow Transplant Program recognized with two hallmarks of quality

The Stem Cell and Bone Marrow Transplant Program at Cedars-Sinai Cancer was recently recognized with two important hallmarks of quality: official accreditation for CAR T-cell therapy, and a third year in a row ranking among the top adult bone marrow transplant programs in the U.S.

31 Jan 2023